Tocilizumab Versus Baricitinib in Patients With Severe COVID-19

• Status: Recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare safety and effectiveness of tocilizumab and baricitinib in severe COVID-19.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital of Patras

Criteria

Inclusion Criteria:

• COVID-19, PaO2/FiO2<200

Exclusion Criteria:

• Age<18 years, Pregnancy, Application of mechanical ventilation prior patients' transfer to our Hospital